New controlled nucleation resource center
![](/46/pdcnewsitem/04/76/79/spscientificpr83-image.jpg)
SP Scientifc's ControLyo Central is a suite of online resources to help freeze dried parenterals manufacturers.
SP Scientific announces ControLyo Central, a new suite of online resources detailing how ControLyo Technology works and its benefits, as well as research publications and brochures. Central to the new resource center are a series of short video presentations assessing the implementation value of new freeze drying technologies to scientific cycle development, production environments, and for financial business impact to freeze dried parenterals manufacturers.
Using an animated video format, SP Scientific introduces the science of ControLyo Technology, the process of implementation, and its potential financial benefits to businesses through factors such as shorter cycle times, reduced waste, and improved product quality.
The video shows how staff at an illustrative pharmaceutical company are faced with slowed production due to lyophilization problems including variations in moisture levels, homogeneity and yield for a new injectable drug. The characters introduce ControLyo Technology and explain in simple terms how the technology affords precise control over the point of freezing during the lyophilization process - a critical factor affecting variability within a batch. Further they describe how ControLyo can reduce cycle time, virtually eliminate waste, improve product quality without requiring any formulation change and maintain sterility. Finally, the cost analysis demonstrates a typical 4-month payback on investment in ControLyo Technology in their production environment.
Additional videos within ControLyo Central include footage of traditional lyophilization versus ControLyo Technology, and 'in action' applications involving lyophilization in both vials and syringes. Visitors to the site will find research publications and supporting literature with Spatially modulated illumination (SMI) microscopy images to further understand this innovative freeze drying breakthrough and its impact on product quality and production efficiencies.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance